Literature DB >> 21387375

Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia.

Eric Lancaster1, Maartje G M Huijbers, Vered Bar, Anna Boronat, Andrew Wong, Eugenia Martinez-Hernandez, Christina Wilson, Dina Jacobs, Meizan Lai, Russell W Walker, Francesc Graus, Luis Bataller, Isabel Illa, Sander Markx, Kevin A Strauss, Elior Peles, Steven S Scherer, Josep Dalmau.   

Abstract

OBJECTIVE: To report clinical and immunological investigations of contactin-associated protein-like 2 (Caspr2), an autoantigen of encephalitis and peripheral nerve hyperexcitability (PNH) previously attributed to voltage-gated potassium channels (VGKC).
METHODS: Clinical analysis was performed on patients with encephalitis, PNH, or both. Immunoprecipitation and mass spectrometry were used to identify the antigen and to develop an assay with Caspr2-expressing cells. Immunoabsorption with Caspr2 and comparative immunostaining of brain and peripheral nerve of wild-type and Caspr2-null mice were used to assess antibody specificity.
RESULTS: Using Caspr2-expressing cells, antibodies were identified in 8 patients but not in 140 patients with several types of autoimmune or viral encephalitis, PNH, or mutations of the Caspr2-encoding gene. Patients' antibodies reacted with brain and peripheral nerve in a pattern that colocalized with Caspr2. This reactivity was abrogated after immunoabsorption with Caspr2 and was absent in tissues from Caspr2-null mice. Of the 8 patients with Caspr2 antibodies, 7 had encephalopathy or seizures, 5 neuropathy or PNH, and 1 isolated PNH. Three patients also had myasthenia gravis, bulbar weakness, or symptoms that initially suggested motor neuron disease. None of the patients had active cancer; 7 responded to immunotherapy and were healthy or only mildly disabled at last follow-up (median, 8 months; range, 6-84 months).
INTERPRETATION: Caspr2 is an autoantigen of encephalitis and PNH previously attributed to VGKC antibodies. The occurrence of other autoantibodies may result in a complex syndrome that at presentation could be mistaken for a motor neuron disorder. Recognition of this disorder is important, because it responds to immunotherapy.
Copyright © 2011 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21387375      PMCID: PMC3059252          DOI: 10.1002/ana.22297

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  22 in total

1.  Molecular organization of the nodal region is not altered in spontaneously diabetic BB-Wistar rats.

Authors:  A A Brown; T Xu; E J Arroyo; S R Levinson; P J Brophy; E Peles; S S Scherer
Journal:  J Neurosci Res       Date:  2001-07-15       Impact factor: 4.164

2.  Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels.

Authors:  S Poliak; L Gollan; R Martinez; A Custer; S Einheber; J L Salzer; J S Trimmer; P Shrager; E Peles
Journal:  Neuron       Date:  1999-12       Impact factor: 17.173

3.  Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates.

Authors:  Beau M Ances; Roberta Vitaliani; Robert A Taylor; David S Liebeskind; Alfredo Voloschin; David J Houghton; Steven L Galetta; Marc Dichter; Abass Alavi; Myrna R Rosenfeld; Josep Dalmau
Journal:  Brain       Date:  2005-05-11       Impact factor: 13.501

4.  Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2.

Authors:  Kevin A Strauss; Erik G Puffenberger; Matthew J Huentelman; Steven Gottlieb; Seth E Dobrin; Jennifer M Parod; Dietrich A Stephan; D Holmes Morton
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

5.  Potassium channel antibodies in two patients with reversible limbic encephalitis.

Authors:  C Buckley; J Oger; L Clover; E Tüzün; K Carpenter; M Jackson; A Vincent
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

6.  Recent progress on the molecular organization of myelinated axons.

Authors:  Steven S Scherer; Edgardo J Arroyo
Journal:  J Peripher Nerv Syst       Date:  2002-03       Impact factor: 3.494

7.  Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations.

Authors:  Kleopas A Kleopa; Lauren B Elman; Bethan Lang; Angela Vincent; Steven S Scherer
Journal:  Brain       Date:  2006-04-13       Impact factor: 13.501

8.  Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome.

Authors:  Jordi Díaz-Manera; Ricard Rojas-García; Eduard Gallardo; Cándido Juárez; Alejandro Martínez-Domeño; Sergi Martínez-Ramírez; Josep Dalmau; Rafael Blesa; Isabel Illa
Journal:  Nat Clin Pract Neurol       Date:  2007-07

9.  Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia.

Authors:  Sarosh R Irani; Sian Alexander; Patrick Waters; Kleopas A Kleopa; Philippa Pettingill; Luigi Zuliani; Elior Peles; Camilla Buckley; Bethan Lang; Angela Vincent
Journal:  Brain       Date:  2010-07-27       Impact factor: 13.501

10.  Juxtaparanodal clustering of Shaker-like K+ channels in myelinated axons depends on Caspr2 and TAG-1.

Authors:  Sebastian Poliak; Daniela Salomon; Hadas Elhanany; Helena Sabanay; Brent Kiernan; Larysa Pevny; Colin L Stewart; Xiaorong Xu; Shing-Yan Chiu; Peter Shrager; Andrew J W Furley; Elior Peles
Journal:  J Cell Biol       Date:  2003-09-08       Impact factor: 10.539

View more
  142 in total

Review 1.  Neuronal surface antibody-mediated autoimmune encephalitis.

Authors:  Jenny J Linnoila; Myrna R Rosenfeld; Josep Dalmau
Journal:  Semin Neurol       Date:  2014-11-04       Impact factor: 3.420

Review 2.  Paraneoplastic disorders in thymoma patients.

Authors:  Amelia Evoli; Eric Lancaster
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

Review 3.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

4.  Autoimmune limbic encephalitis.

Authors:  T Wingfield; C McHugh; A Vas; A Richardson; E Wilkins; A Bonington; A Varma
Journal:  Clin Med (Lond)       Date:  2012-02       Impact factor: 2.659

5.  Long-term clinical course with voltage-gated potassium channel antibody in Morvan's syndrome.

Authors:  Nam-Hee Kim; Angela Vincent; Saroshi R Irani; Sang Eun Kim; Kwang-Woo Lee; Kyung Seok Park
Journal:  J Neurol       Date:  2013-07-28       Impact factor: 4.849

Review 6.  Recognizing Autoimmune-Mediated Encephalitis in the Differential Diagnosis of Limbic Disorders.

Authors:  A J da Rocha; R H Nunes; A C M Maia; L L F do Amaral
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-17       Impact factor: 3.825

7.  Caspr2-reactive antibody cloned from a mother of an ASD child mediates an ASD-like phenotype in mice.

Authors:  L Brimberg; S Mader; V Jeganathan; R Berlin; T R Coleman; P K Gregersen; P T Huerta; B T Volpe; B Diamond
Journal:  Mol Psychiatry       Date:  2016-10-04       Impact factor: 15.992

8.  Limbic encephalitis and related cortical syndromes.

Authors:  Ignacio Rubio-Agusti; Miguel Salavert; Luis Bataller
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

9.  Molecular Architecture of Contactin-associated Protein-like 2 (CNTNAP2) and Its Interaction with Contactin 2 (CNTN2).

Authors:  Zhuoyang Lu; M V V V Sekhar Reddy; Jianfang Liu; Ana Kalichava; Jiankang Liu; Lei Zhang; Fang Chen; Yun Wang; Luis Marcelo F Holthauzen; Mark A White; Suchithra Seshadrinathan; Xiaoying Zhong; Gang Ren; Gabby Rudenko
Journal:  J Biol Chem       Date:  2016-09-12       Impact factor: 5.157

10.  Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies.

Authors:  Mar Petit-Pedrol; Thaís Armangue; Xiaoyu Peng; Luis Bataller; Tania Cellucci; Rebecca Davis; Lindsey McCracken; Eugenia Martinez-Hernandez; Warren P Mason; Michael C Kruer; David G Ritacco; Wolfgang Grisold; Brandon F Meaney; Carmen Alcalá; Peter Sillevis-Smitt; Maarten J Titulaer; Rita Balice-Gordon; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2014-01-22       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.